Evidence map›Paper›PMID 30905644›Full record

ArticleOphthalmology2019

Loss-of-Function Mutations in the CFH Gene Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular Drusen.

Rachel L Taylor, James A Poulter, Susan M Downes, Martin McKibbin, Kamron N Khan, Chris F Inglehearn, Andrew R Webster, Alison J Hardcastle, Michel Michaelides, Paul N Bishop and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evidence for the Pathogenicity of aMedicina (Kaunas, Lithuania) · 2025
    Article
  5. Early-onset macular drusen, a monogenic form of age-related macular degeneration.American journal of ophthalmology case reports · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. The human factor H protein family - an update.Frontiers in immunology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. The complement system in age-related macular degeneration.Cellular and molecular life sciences : CMLS · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Rachel L TaylorDivision of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, St. Mary's Hospital, Manchester, United Kingdom.
James A PoulterSection of Ophthalmology and Neuroscience, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
Susan M DownesOxford Eye Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford, United Kingdom; Nuffield Department of Clinical Neuroscience, John Radcliffe Hospital, Oxford, United Kingdom.
Martin McKibbinDepartment of Ophthalmology, St. James's University Hospital, Leeds, United Kingdom.
Kamron N KhanSection of Ophthalmology and Neuroscience, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
Chris F InglehearnSection of Ophthalmology and Neuroscience, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
Andrew R WebsterUCL Institute of Ophthalmology, University College London, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom.
Alison J HardcastleUCL Institute of Ophthalmology, University College London, London, United Kingdom.
Michel MichaelidesUCL Institute of Ophthalmology, University College London, London, United Kingdom; Moorfields Eye Hospital, London, United Kingdom.
Paul N BishopDivision of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; Manchester Royal Eye Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Simon J ClarkDivision of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; The Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
Graeme C BlackDivision of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, St. Mary's Hospital, Manchester, United Kingdom. Electronic address: graeme.black@manchester.ac.uk.
United Kingdom Inherited Retinal Dystrophy Consortium
Manchester Academic Health Science Centre · GBUniversity of Leeds · GBMoorfields Eye Hospital NHS Foundation Trust · GBJohn Radcliffe Hospital · GBMoorfields Eye Hospital · GBSt James's University Hospital · GBUniversity College London · GB

Funding

Medical Research Council MR/K024418/1Medical Research Council MR/R024952/1Medical Research Council MR/R042952/1
6 · The paper itself

Abstract

purposeTo characterize the molecular mechanism underpinning early-onset macular drusen (EOMD), a phenotypically severe subtype of age-related macular degeneration (AMD), in a subgroup of patients.

designMulticenter case series, in vitro experimentation, and retrospective analysis of previously reported variants.

participantsSeven families with apparently autosomal dominant EOMD.

methodsPatients underwent a comprehensive ophthalmic assessment. Affected individuals from families A, B, and E underwent whole exome sequencing. The probands from families C, D, F, and G underwent Sanger sequencing analysis of the complement factor H (CFH) gene. Mutant recombinant factor H like-1 (FHL-1) proteins were expressed in HEK293 cells to assess the impact on FHL-1 expression and function. Previously reported EOMD-causing variants in CFH were reviewed.

main outcome measuresDetailed clinical phenotypes, genomic findings, in vitro characterization of mutation effect on protein function, and postulation of the pathomechanism underpinning EOMD.

resultsAll affected participants demonstrated bilateral drusen. The earliest reported age of onset was 16 years (median, 46 years). Ultra-rare (minor allele frequency [MAF], ≤0.0001) CFH variants were identified as the cause of disease in each family: CFH c.1243del, p.(Ala415ProfsTer39) het; c.350+1G→T het; c.619+1G→A het, c.380G→A, p.(Arg127His) het; c.694C→T p.(Arg232Ter) het (identified in 2 unrelated families in this cohort); and c.1291T→A, p.(Cys431Ser). All mutations affect complement control protein domains 2 through 7, and thus are predicted to impact both FHL-1, the predominant isoform in Bruch's membrane (BrM) of the macula, and factor H (FH). In vitro analysis of recombinant proteins FHL-1

conclusionsEarly-onset macular drusen is an underrecognized, phenotypically severe subtype of AMD. We propose that haploinsufficiency of FHL-1, the main regulator of the complement pathway in BrM, where drusen develop, is an important mechanism underpinning the development of EOMD in a number of cases. Understanding the molecular basis of EOMD will shed light on AMD pathogenesis given their pathologic similarities.

Indexed as

MutationAgedComplement Factor HFemaleGenetic VariationHumansIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMaleMiddle AgedMuscle ProteinsRetinal DrusenRetrospective StudiesComplement Factor HFHL1 protein, humanIntracellular Signaling Peptides and ProteinsLIM Domain ProteinsMuscle Proteins

Identifiers

PMID30905644
PMCPMC6856713
OpenAlexW2924621218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.